Skip To Main Content
Zhongyin Yang on Muck Rack

Zhongyin Yang

As seen in: JAMA Oncology, EJNMMI Research, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zhongyin

Contact Zhongyin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis : A Phase 3 Randomized Clinical Trial

|
By Zhongyin Yang, Zheng Shi, Sheng Lu, Min Shi, Mingming Nie, Jian Chen, Dan Wu, Yiping Mou, Yunyun Xu, Yanong Wang, Xiaowen Liu, Hui cao, Jiayi Gu, Jiren Yu, Kai Liu, Xinchun Liu, Jun Zhang, Kai Yin, Zhenggang Zhu
| JAMA Oncology Verified
Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: A Phase 3 Randomized Clinical Trial Supplement 1. Supplement 2. Statistical analysis plan Supplement 3. eTable 1. Eligibility and Exclusion Criteria eMethods. Dose Modification Rules eFigure 1. Study Treatment Schema eFigure 2. Overall Survival in the Full Intention-to-Treat Population eFigure 3. Piecewise Cox Analysis of Time-Varying Treatment Effect on Overall Survival eFigure 4.
Open in Who Shared Issue with article?

Preoperative assessment and prognostic prediction of gastric cancer patients with peritoneal metastasis using 18F-FDG PET/CT before conversion surgery | EJNMMI Research | Full Text

|
By Yao Peng, Daxi Xiong, Sheng Lu, Ying Miao, Hong Yuan, Zhenggang Zhu, Biao Li, Zhongyin Yang, Jiajia Hu
| EJNMMI Research Verified
This single-centre retrospective study was approved by the Ruijin Hospital Ethics Committee of Shanghai Jiao Tong University School of Medicine (Ethics Committee Reference Number: 2024-59). GC patients with PM who underwent 18F-FDG PET/CT scans after conversion therapy between September 2015 and July 2023 in Ruijin Hospital affiliated with the Shanghai Jiao Tong University School of Medicine were enrolled in this study.
Open in Who Shared Issue with article?

Sintilimab combined neoadjuvant intraperitoneal and systemic chemotherapy in gastric cancer with peritoneal metastasis | Future Oncology

|
By Hong Yuan, Sheng Lu, Wentao Liu, Zhongyin Yang
| Future Medicine Verified
Future OncologyAhead of Print Clinical Trial ProtocolOpen Access , , , , , , , , , , , , , , , , , , & Published Online: Abstract Intraperitoneal chemotherapy combined with systemic chemotherapy is one of the therapeutic modalities currently used for the treatment of gastric cancer patients with peritoneal metastasis. This study was designed to evaluate the efficacy and safety of sintilimab plus S-1 combined intraperitoneal and intravenous paclitaxel.
Open in Who Shared Issue with article?
See all 3 articles